{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:25:42Z","timestamp":1791314742128,"version":"4.3.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2014,2,11]]},"abstract":"<jats:sec>\n            <jats:title>Background\u2014<\/jats:title>\n            <jats:p>Lipoprotein(a) [Lp(a)] is a low-density lipoprotein\u2013like particle largely independent of known risk factors and predictive of cardiovascular disease. Statins may offset the risk associated with elevated Lp(a), but it is unknown whether Lp(a) is a determinant of residual risk in the setting of low low-density lipoprotein cholesterol after potent statin therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and Results\u2014<\/jats:title>\n            <jats:p>\n              Baseline and on-treatment Lp(a) concentrations were assessed in 9612 multiethnic participants in the JUPITER trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) before and after random allocation to rosuvastatin 20 mg\/d or placebo, with outcomes reported for whites (n=7746). Lp(a) concentrations (median [25th\u201375th percentile], in nmol\/L) were highest in blacks (60 [34\u2013100]), then Asians (38 [18\u201360]), Hispanics (24 [11\u201346]), and whites (23 [10\u201350];\n              <jats:italic>P<\/jats:italic>\n              &lt;0.001). Although the median change in Lp(a) with rosuvastatin and placebo was zero, rosuvastatin nonetheless resulted in a small but statistically significant positive shift in the overall Lp(a) distribution (\n              <jats:italic>P<\/jats:italic>\n              &lt;0.0001). Baseline Lp(a) concentrations were associated with incident cardiovascular disease (adjusted hazard ratio per 1-SD increment in Ln[Lp(a)], 1.18; 95% confidence interval, 1.03\u20131.34;\n              <jats:italic>P<\/jats:italic>\n              =0.02). Similarly, on-statin Lp(a) concentrations were associated with residual risk of cardiovascular disease (adjusted hazard ratio, 1.27; 95% confidence interval, 1.01\u20131.59;\n              <jats:italic>P<\/jats:italic>\n              =0.04), which was independent of low-density lipoprotein cholesterol and other factors. Rosuvastatin significantly reduced incident cardiovascular disease among participants with baseline Lp(a) greater than or equal to the median (hazard ratio, 0.62; 95% confidence interval, 0.43\u20130.90) and Lp(a) less than the median (hazard ratio, 0.46; 95% confidence interval, 0.30\u20130.72), with no evidence of interaction. Similar results were obtained when analyses included nonwhites.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion\u2014<\/jats:title>\n            <jats:p>Among white JUPITER participants treated with potent statin therapy, Lp(a) was a significant determinant of residual risk. The magnitude of relative risk reduction with rosuvastatin was similar among participants with high or low Lp(a).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical Trials Registration\u2014<\/jats:title>\n            <jats:p>\n              URL:\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">http:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n              . Unique identifier: NCT00239681.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/circulationaha.113.004406","type":"journal-article","created":{"date-parts":[[2013,11,18]],"date-time":"2013-11-18T01:14:04Z","timestamp":1384737244000},"page":"635-642","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":433,"title":["Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk"],"prefix":"10.1161","volume":"129","author":[{"given":"Amit V.","family":"Khera","sequence":"first","affiliation":[{"name":"From the Division of Preventive Medicine (A.V.K., B.M.E., P.M.R., S.M.) and Division of Cardiovascular Medicine (B.M.E., P.M.R., S.M.), Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA; and Quest Diagnostics Nichols Institute, San Juan Capistrano, CA (M.P.C., F.M.H., J.W.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan M.","family":"Everett","sequence":"additional","affiliation":[{"name":"From the Division of Preventive Medicine (A.V.K., B.M.E., P.M.R., S.M.) and Division of Cardiovascular Medicine (B.M.E., P.M.R., S.M.), Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA; and Quest Diagnostics Nichols Institute, San Juan Capistrano, CA (M.P.C., F.M.H., J.W.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Caulfield","sequence":"additional","affiliation":[{"name":"From the Division of Preventive Medicine (A.V.K., B.M.E., P.M.R., S.M.) and Division of Cardiovascular Medicine (B.M.E., P.M.R., S.M.), Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA; and Quest Diagnostics Nichols Institute, San Juan Capistrano, CA (M.P.C., F.M.H., J.W.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feras M.","family":"Hantash","sequence":"additional","affiliation":[{"name":"From the Division of Preventive Medicine (A.V.K., B.M.E., P.M.R., S.M.) and Division of Cardiovascular Medicine (B.M.E., P.M.R., S.M.), Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA; and Quest Diagnostics Nichols Institute, San Juan Capistrano, CA (M.P.C., F.M.H., J.W.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Wohlgemuth","sequence":"additional","affiliation":[{"name":"From the Division of Preventive Medicine (A.V.K., B.M.E., P.M.R., S.M.) and Division of Cardiovascular Medicine (B.M.E., P.M.R., S.M.), Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA; and Quest Diagnostics Nichols Institute, San Juan Capistrano, CA (M.P.C., F.M.H., J.W.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M","family":"Ridker","sequence":"additional","affiliation":[{"name":"From the Division of Preventive Medicine (A.V.K., B.M.E., P.M.R., S.M.) and Division of Cardiovascular Medicine (B.M.E., P.M.R., S.M.), Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA; and Quest Diagnostics Nichols Institute, San Juan Capistrano, CA (M.P.C., F.M.H., J.W.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Mora","sequence":"additional","affiliation":[{"name":"From the Division of Preventive Medicine (A.V.K., B.M.E., P.M.R., S.M.) and Division of Cardiovascular Medicine (B.M.E., P.M.R., S.M.), Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA; and Quest Diagnostics Nichols Institute, San Juan Capistrano, CA (M.P.C., F.M.H., J.W.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60367-5"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.04.038"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1699-0463.1963.tb01808.x"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00455a007"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1063"},{"key":"e_1_3_4_7_2","first-page":"2499","article-title":"Lipid-related markers and cardiovascular disease prediction.","volume":"307","author":"The Emerging Risk Factors Collaboration","year":"2012","unstructured":"The Emerging Risk Factors CollaborationDi Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, Thompson A, Butterworth AS, Sarwar N, Wormser D, Saleheen D, Ballantyne CM, Psaty BM, Sundstr\u00f6m J, Ridker PM, Nagel D, Gillum RF, Ford I, Ducimetiere P, Kiechl S, Koenig W, Dullaart RP, Assmann G, D\u2019Agostino RB, Dagenais GR, Cooper JA, Kromhout D, Onat A, Tipping RW, G\u00f3mez-de-la-C\u00e1mara A, Rosengren A, Sutherland SE, Gallacher J, Fowkes FG, Casiglia E, Hofman A, Salomaa V, Barrett-Connor E, Clarke R, Brunner E, Jukema JW, Simons LA, Sandhu M, Wareham NJ, Khaw KT, Kauhanen J, Salonen JT, Howard WJ, Nordestgaard BG, Wood AM, Thompson SG, Boekholdt SM, Sattar N, Packard C, Gudnason V, Danesh J. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012;307:2499\u20132506.","journal-title":"JAMA"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902604"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.801"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03530220037029"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60447-5"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.12.035"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60713-1"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2011.180281"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2003.023689"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq386"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.11.1363"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(89)90218-9"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2009.03994.x"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100670200127"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.111.045120"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2010.146779"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.1997.tb04342.x"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(99)00259-2"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1989.tb01393.x"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107579"},{"key":"e_1_3_4_28_2","unstructured":"Merck announces HPS2-THRIVE Study of TREDAPTIVE (extended-release niacin\/laropiprant) did not achieve primary endpoint [news release]. Whitehouse Station NJ: Merck; December 20 2012. http:\/\/www.mercknewsroom.com\/press-release\/prescription-medicine-news\/merck-announces-hps2-thrive-study-tredaptive-extended-relea. Accessed January 11 2013."},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009744"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105803"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2010.01.003"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.10.052"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.113.004406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T06:31:44Z","timestamp":1715581904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.113.004406"}},"subtitle":["An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)"],"short-title":[],"issued":{"date-parts":[[2014,2,11]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,2,11]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.113.004406"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.113.004406","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,11]]},"assertion":[{"value":"2013-06-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-10-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-11-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}